The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.
1. Introduction - p. 648 2. Clinical diagnosis and prognosis of COVID-19 - p. 649 3. COVID-19: Basic concepts and mechanisms - p. 653 4. Long COVID - p. 663 5. CS/CSDNV dynamics in corona viral infection - p. 666 6. Treatment of COVID-19 infection - p. 666 7. NTs interventions in COVID-19 infection - p. 675 8. Transcriptional regulation of CS/CSDNV dynamics by physical exercise in COVID-19 infection - p. 680 9. COVID-19 NTs (Recent Trends and future developments) - p. 684 10. Conclusion - p. 688 11. Chapter 52 Charnolosome nanotheranostics in Mitochondrial Nanomedicine - p. 697 12. Chapter 53 Charnolosome-based disease-specific nanotherapeutics - p. 713 13. Chapter 54 Physiological, biochemical, pharmacological, and genetic manipulations of charnolosome in personalized nanotheranostics of chronic MDR diseases - p. 729 14. Chapter 55 Transcriptional and translational regulation of charnolosome in multidrug-resistant malignancies and other chronic diseases - p. 745 15. Chapter 56 Future prospects of charnolosome in evidence-based personalized nanotheranostics - p. 757 16. Index - p. 795
The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.
1. Introduction - p. 648 2. Clinical diagnosis and prognosis of COVID-19 - p. 649 3. COVID-19: Basic concepts and mechanisms - p. 653 4. Long COVID - p. 663 5. CS/CSDNV dynamics in corona viral infection - p. 666 6. Treatment of COVID-19 infection - p. 666 7. NTs interventions in COVID-19 infection - p. 675 8. Transcriptional regulation of CS/CSDNV dynamics by physical exercise in COVID-19 infection - p. 680 9. COVID-19 NTs (Recent Trends and future developments) - p. 684 10. Conclusion - p. 688 11. Chapter 52 Charnolosome nanotheranostics in Mitochondrial Nanomedicine - p. 697 12. Chapter 53 Charnolosome-based disease-specific nanotherapeutics - p. 713 13. Chapter 54 Physiological, biochemical, pharmacological, and genetic manipulations of charnolosome in personalized nanotheranostics of chronic MDR diseases - p. 729 14. Chapter 55 Transcriptional and translational regulation of charnolosome in multidrug-resistant malignancies and other chronic diseases - p. 745 15. Chapter 56 Future prospects of charnolosome in evidence-based personalized nanotheranostics - p. 757 16. Index - p. 795
